BR0207932A - Composições farmacêuticas de sabor mascarado - Google Patents

Composições farmacêuticas de sabor mascarado

Info

Publication number
BR0207932A
BR0207932A BR0207932-1A BR0207932A BR0207932A BR 0207932 A BR0207932 A BR 0207932A BR 0207932 A BR0207932 A BR 0207932A BR 0207932 A BR0207932 A BR 0207932A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
microcapsule
masked taste
taste pharmaceutical
taste
Prior art date
Application number
BR0207932-1A
Other languages
English (en)
Inventor
Stephen A Ulrich
Karen R Zimm
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0207932A publication Critical patent/BR0207932A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

"COMPOSIçõES FARMACêUTICAS DE SABOR MASCARADO". A presente invenção refere-se a uma composição farmacêutica de sabor mascarado compreendendo uma microcápsula, em que a micro-cápsula compreende um núcleo de agente farmaceuticamente ativo com uma quantidade eficaz para mascaramento de sabor de um revestimento entérico insolúvel em água, em que o revestimento compreende um copolímero fracamente ácido de ácido metacrílico - acrilato de etila.
BR0207932-1A 2001-03-05 2002-02-26 Composições farmacêuticas de sabor mascarado BR0207932A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27347301P 2001-03-05 2001-03-05
PCT/US2002/005795 WO2002069939A2 (en) 2001-03-05 2002-02-26 Taste masked pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0207932A true BR0207932A (pt) 2004-03-02

Family

ID=23044085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207932-1A BR0207932A (pt) 2001-03-05 2002-02-26 Composições farmacêuticas de sabor mascarado

Country Status (12)

Country Link
US (1) US6767557B2 (pt)
EP (1) EP1370247B1 (pt)
JP (1) JP2004520420A (pt)
AT (1) ATE391496T1 (pt)
AU (1) AU2002254036A1 (pt)
BR (1) BR0207932A (pt)
CA (1) CA2440069A1 (pt)
DE (1) DE60226012T2 (pt)
HK (1) HK1058482A1 (pt)
MX (1) MXPA03008057A (pt)
MY (1) MY129317A (pt)
WO (1) WO2002069939A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1492511E (pt) * 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
WO2003084517A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
EP1656117A1 (en) * 2003-08-11 2006-05-17 Merck Frosst Canada Ltd. Flavored taste-masked pharmaceutical formulation made using a one-step coating process
US20060013834A1 (en) * 2004-02-24 2006-01-19 Medicis Pediatrics, Inc. Room temperature stable aqueous liquid pharmaceutical composition
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US20060216355A1 (en) * 2005-03-28 2006-09-28 Donald Spector Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
US9023382B2 (en) * 2005-06-08 2015-05-05 Basf Corporation Medicament carrier composition and method of forming a film therefrom
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US8304226B2 (en) * 2006-08-22 2012-11-06 Carl Miller Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine
US8007783B2 (en) * 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
WO2008098586A1 (en) 2007-02-13 2008-08-21 Dafra Pharma N.V. Pharmaceutical carrier composition and pharmaceutical composition
JP2010530408A (ja) * 2007-06-18 2010-09-09 ドルハイ クリニカ エゲースセーギュジ ケーエフティー． 殺生物性カプセル、それらを含む製剤、及び該製剤を含む衛生パッド
US20090065225A1 (en) * 2007-09-07 2009-03-12 Black & Decker Inc. Switchable anti-lock control
DK2403482T3 (en) * 2009-03-04 2018-03-05 Emplicure Ab ABUSE RESISTANT FORMULATION
CN102421419B (zh) 2009-05-08 2016-05-04 奥瑞克索股份公司 用于持续药物传递的包含地聚合物粘合剂的组合物
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
US20130115300A1 (en) 2010-04-12 2013-05-09 Uma Rajan Javeri Ciprofloxacin dry syrup composition
PL2613784T3 (pl) 2010-09-07 2018-05-30 Emplicure Ab Wyrób do przezskórnego podawania leku
JP5976657B2 (ja) 2011-09-30 2016-08-24 持田製薬株式会社 易服用性固形製剤
EP2804613A4 (en) 2012-01-16 2015-12-09 Elizabeth Mckenna COMPOSITIONS AND METHODS FOR TREATING DISEASES AND HEPATIC DISORDERS
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
WO2014143935A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
MX365914B (es) 2013-03-15 2019-06-20 Aprecia Pharmaceuticals LLC Forma de dosificación de topiramato dispersable rápidamente.
US10098964B2 (en) 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
JP6294400B2 (ja) * 2016-07-19 2018-03-14 持田製薬株式会社 易服用性固形製剤
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
WO2020255837A1 (ja) * 2019-06-17 2020-12-24 東和薬品株式会社 時限式溶出マスキング粒子およびそれを含有する経口医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
CA2338996A1 (en) * 1998-07-31 2000-02-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition having improved taste
CZ20014379A3 (cs) * 1999-06-11 2002-08-14 Ranbaxy Laboratories Limited Kompozice k maskování chuti a způsob její přípravy
IN192159B (pt) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
US6767557B2 (en) 2004-07-27
WO2002069939A3 (en) 2003-03-13
HK1058482A1 (en) 2004-05-21
WO2002069939A2 (en) 2002-09-12
JP2004520420A (ja) 2004-07-08
DE60226012T2 (de) 2009-05-14
CA2440069A1 (en) 2002-09-12
MXPA03008057A (es) 2004-10-15
EP1370247A2 (en) 2003-12-17
EP1370247B1 (en) 2008-04-09
AU2002254036A1 (en) 2002-09-19
MY129317A (en) 2007-03-30
ATE391496T1 (de) 2008-04-15
DE60226012D1 (de) 2008-05-21
US20020197327A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
BR0207932A (pt) Composições farmacêuticas de sabor mascarado
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
CO5190681A1 (es) Formas de dosificacion farmaceutica para la liberacion controlada que producen al menos un impulso ciclico
WO2002011702A3 (en) Hydrogel-driven drug dosage form
HRP20050625A2 (en) Modified-release tablet of bupropion hydrochloride
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
AP1748A (en) Chronotherapeutic dosage forms.
CA2395333A1 (en) Hydrogel-driven drug dosage form
ATE361061T1 (de) Beschichtungszusammensetzung zur geschmacksmaskierung
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
IT1289160B1 (it) Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
BR0109925A (pt) Composição de revestimento para mascaramento de paladar
DE60112656D1 (de) Beschichtungszusammensetzung, Beschichtungsverfahren und beschichteter Gegenstand
DE60105665D1 (de) Beschichtungszusammensetzung, Beschichtungsverfahren und beschichtete Gegenstände
WO2002024174A3 (en) Sustained release composition containing clarithromycin
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2004052345A8 (en) Coating composition for taste masking coating and methods for their application and use
EA200300110A1 (ru) Композиция элетриптана в виде частиц
DE60001302D1 (de) Wässrige Beschichtungszusammensetzung
ZA200306545B (en) Medicinal compositions comprising diclofenac and ornoprostil.
BR0210096A (pt) Composição farmacêutica contendo emoliente de fezes tal como poloxâmero e partìculas entéricas revestidas de bissacodil
AR033431A1 (es) Composiciones farmaceuticas de sabor enmascarado.
WO2002062299A3 (en) Improved controlled release oral dosage form
DE60124839D1 (de) Wässrige Beschichtungszusammensetzung

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: JOHNSON & JOHNSON (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/52, 31/5383, 9/10; A61P 31/04, 31/00

Ipc: A61K 9/52 (2011.01), A61K 31/5383 (2011.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.